50. 皮膚筋炎／多発性筋炎 Dermatomyositis Clinical trials / Disease details

臨床試験数 : 194 / 薬物数 : 244 - (DrugBank : 89) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 151

4 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2200059159	2022-04-26	2022-04-26	Efficacy and safety of triple therapy based on prognostic risk stratification in patients with anti-MDA5 antibody-positive dermatomyositis: a multicenter, prospective, randomized controlled study	Efficacy and safety of triple therapy based on prognostic risk stratification in patients with anti-MDA5 antibody-positive dermatomyositis: a multicenter, prospective, randomized controlled study	anti-MDA5 antibody-positive dermatomyositis	experimental group:High-dose glucocorticoid + cyclophosphamide + calcineurin inhibitor;control group:High-dose glucocorticoid + cyclophosphamide or calcineurin inhibitor;	First Affiliated Hospital of Nanjing Medical University	NULL	Pending	18	100	Both	experimental group:60;control group:60;	Phase 4	China
2	ChiCTR2000036709	2020-10-01	2020-08-24	Study on early warning of rapid progressive interstitial lung disease in dermatomyositis	Study on early warning of rapid progressive interstitial lung disease in dermatomyositis	Dermatomyositis	Group 1:Glucocorticoid + cyclophosphamide + cyclosporin;Group 2:Glucocorticoid + cyclophosphamide + Tofacitinib;	Zhongshan Hospital of Fudan University	NULL	Pending	18	60	Both	Group 1:15;Group 2:15;	N/A	China
3	EUCTR2012-003633-42-GB (EUCTR)	18/10/2013	22/08/2013	A trial of rituximab compared to usual best care in patients with interstitial (inflammatory or scarring conditions) lung disease due to systemic autoimmune (connective tissue) diseases	A randomized, double blind controlled trial comparing rituximab against intravenous cyclophosphamide in connective tissue disease associated interstitial lung disease - Rituximab versus cyclophosphamide in connective tissue disease-ILD	A diagnosis of connective tissue disease associated interstitial lung disease, based on internationally accepted criteria, in one of the following categories: o Systemic sclerosis o Idiopathic interstitial myopathy (including polymyositis/dermatomyositis) o Mixed connective tissue disease MedDRA version: 14.1;Level: PT;Classification code 10012503;Term: Dermatomyositis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders MedDRA version: 14.1;Classification code 10022611;Term: Interstitial lung disease;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 14.1;Classification code 10027754;Term: Mixed connective tissue disease;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 14.1;Classification code 10039710;Term: Scleroderma;Classification code 10036102;Term: Polymyositis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Trade Name: MabThera Product Name: Rituximab INN or Proposed INN: Rituximab Trade Name: Cyclophosphamide Injection 1g Product Name: Cyclophosphamide Injection 1g INN or Proposed INN: Cyclophosphamide	Royal Brompton and Harefield NHS Foundation Trust	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			United Kingdom
4	JPRN-UMIN000031931	2010/12/01	27/03/2018	Phase 2 trial of autologous hematopoietic stem cell transplantation for severe dermatomyositis	Phase 2 trial of autologous hematopoietic stem cell transplantation for severe dermatomyositis - Autologous hematopoietic stem cell transplantation for severe dermatomyositis	Dermatomyositis	Cyclophosphamide 2g/m2, 2 days Harvest of autologous hematopoietic stem cells Cyclophosphamide 50mg/kg, 4 days Transplantation of autologous hematopoietic stem cells	Kyushu University	NULL	Complete: follow-up complete	16years-old	65years-old	Male and Female	10	Phase 2	Japan